In this issue:
Persistence and remission with guselkumab vs IL-17 inhibitors
Dupilumab up to 1 year in children with atopic dermatitis
Erenumab for persistent erythema and flushing in rosacea
Guselkumab for pityriasis rubra pilaris
Patient-reported outcomes for psoriasis treated with biologics
Vaccination rates among patients on biologics
Vaccination recommendations for biologics and oral treatments
Inflammatory cytokines during omalizumab in chronic spontaneous urticaria
Biologics and all-cause mortality in patients with psoriasis
Secukinumab for moderate-to-severe hidradenitis suppurativa
Please login below to download this issue (PDF)